Join TaNeDS Global 2019

Learn more about Daiichi Sankyo's open competition grant program

TaNeDS
Take A New Challenge For Drug Discovery

Passion for Innovation.
Compassion for Patients.™

Daiichi-Sankyo

Join TaNeDS Global 2019

Learn more about Daiichi Sankyo's open competition grant program

What is TaNeDS?

TaNeDS (Take a New Challenge for Drug diScovery) program provides close partnership between you and scientists in Daiichi Sankyo to tackle unmet medical needs. In this program, we provide Our Research Interests and collect Application Forms from principal investigators affiliated with research institution in academia and small biotech located in Europe and the United States. After careful review by selected members of Daiichi Sankyo, we start the collaboration research with the winners of this program.

The Deadline of Submission is February 15, 2019



Our Research Interests

- Oncology
- Cardiovascular and renal diseases
- Other diseases
- Technology and related research
- Pain/Neuroscience
- Rare diseases
- Cell therapy

For more detailed research interests, please visit : www.daiichisankyo.com/rd/taneds/theme/

Advantage of TaNeDS collaboration

- Access to novel technologies and close collaboration with researchers in Daiichi Sankyo
  We can provide chemical compounds and novel technologies (Antibody-Drug Conjugate [ADC], chemically modified oligonucleotides [ENA^{R} oligonucleotide], low-/mid-sized protein scaffolds together with panning technology, etc.). We can screen small compounds targeting your molecule of interest.
- Possible extended collaboration after TaNeDS program
  Our collaboration can be extended once success criteria is achieved.

Basic Policy of TaNeDS Contract

- Intellectual Property (IP)
  Ownership of IPs generated in TaNeDS collaboration research will be determined according to the inventorship. Daiichi Sankyo would like to have exclusive negotiation right to obtain an exclusive or non-exclusive license for IPs generated in TaNeDS collaboration research.
- Publication
  The results of TaNeDS collaboration research shall not be published without Daiichi Sankyo's prior written consent according to the agreement executed between your institution and Daiichi Sankyo. Daiichi Sankyo may ask you to consider appropriate timing or amendments of the publication.

For more information, please visit our website at www.daiichisankyo.com/rd/taneds/

Guidelines for Application

Candidate Profile

- Researchers affiliated with universities, research institutions and/or small biotech in Europe and the United States of America.
- Europe：EU plus Iceland, Norway, Switzerland and Israel
- The United States of America：50 states and Washington D.C.
- TaNeDS Global is not open to undergraduate and graduate students.

Selection Criteria

- Matching needs (Research Interests)
- Originality and uniqueness of research
- Possibllity for drug generation program
- Feasibility of research plan
- Non-redundancy with Daiichi Sankyo's internal research projects and current collaboration

Research Period

- Two years

Funding Size

- Type A：€ (Europe) / $ (US) 50,000 – 75,000 per year, plus overhead
- Type B：€ (Europe) / $ (US) 100,000 – 150,000 per year, plus overhead

Important Dates and Deadlines

- Start date for submission of applications：January 9, 2019, 7:00 UTC
- Submission deadline：February 15, 2019
- Notification of preliminary decisions：Mid-March, 2019
- Inquiry for confidential information under CDA：Late-March to April, 2019
- On-site visit interview：Mid-May, 2019
- Notification of final decisions：Mid-June, 2019

Who we are

Daiichi Sankyo Co., Ltd. is a proprietary pharmaceutical company with origins in Japan and has over 100 years of history in drug discovery and development. Our R&D innovation and successes include a member of the statin class Pravastatin (Pravachol®：US, EU, licensed to Bristol-Myers Squibb) and the new Quinolone class Levofloxacin (Levaquin®：US, licensed to Johnson & Johnson, Tavanic®：EU, licensed to Sanofi Aventis). Recent drugs include the angiotensin receptor blocker Olmesartan (Benicar®：US, Olmetec®：EU), the ADP receptor inhibitor Prasugrel (Effient®：US, Efient®：EU, co-promoted with Eli Lilly), and the FXa inhibitor Edoxaban (Savaysa®：US, Lixiana®：EU). Our worldwide research and development network connects Japan, the United States, Europe, and East Asian countries. In Europe, the Tissue and Cell Research Center Munich performs pharmacokinetic studies and toxicity tests. In the United States, Plexxikon Inc., based in Berkeley, California, is advancing R&D for oncology, from research to early-stage development.

For more information, please visit : www.daiichisankyo.com

Daiichi Sankyo Co, Ltd.
Shinagawa R&D Center

www.daiichisankyo.com/rd/taneds/

For more information, please visit our website at
www.daiichisankyo.com/rd/taneds/